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- (3) Controls: biopsies were taken from the anterior rectal 
wall only. 
 
 
 
Total sample protein was extracted. Cytokine levels were 
evaluated using 3 independent panels detecting the presence 
and concentrations of 30 different cytokines. A histology 
score for radiation enteropathy (*) was used to characterize 
the samples. Higher scores reflect worse outcomes.  
Significance was studied with the Kruskal-Wallis, Wilcoxon 
and Student’s t-test. 
 
Results: Recruitment ran from April 2014 to January 2015. 9 
symptomatic patients, treated with prostate irradiation at 
least 2 years before and 6 healthy controls were recruited.  
Cytokine concentrations were higher in controls and in 
biopsies taken from normal tissue in the patients. Although 
patient samples from areas without disease had globally 
higher cytokine levels when compared to areas with disease, 
this was not significant. There was a trend to slightly higher 
histology scores in biopsies from irradiated tissues (table 1).  
 
 
 
Conclusion: Cytokine levels are decreased in human tissues 
with late radiation enteropathy. This may reflect a protective 
function of cytokines, either in the maintenance of the 
mucosal barrier or in keeping a normal balance of gut 
microbiota. Pathway analysis and modeling of the 
inflammatory response will be the object of further analyses.  
 
PV-0431  
Changes of the density CD8+ tumour infiltrating 
lymphocytes after neoadjuvant radiochemotherapy 
D. Buka
1University Hospital Hradec Kralove, Oncology and 
Radiotherapy Department, Hradec Kralove, Czech Republic 
1, J. Dvorak2, V. Sitorova3, I. Richter4, I. Sirak1 
2Charles University and Thomayer Hospital, Department of 
Oncology- First Faculty of Medicine, Prague, Czech Republic 
3University Hospital Hradec Kralove, Department of 
Pathology- Charles University, Hradec Kralove, Czech 
Republic 
4Regional Hospital Liberec, Department of Oncology, Liberec, 
Czech Republic 
 
Purpose or Objective: The aim of this retrospective study is 
to evaluate the effect of neoadjuvant radiochemotherapy on 
the density of CD8+ tumor infiltrating lymphocytes (TILs) of 
rectal adenocarcinoma, by comparison of the density of CD8+ 
TILs in endoscopical biopsies before and resection specimens 
after the therapy. 
 
Material and Methods: In total 53 patients with locally 
advanced rectal cancer were studied retrospectively. 
Neoadjuvant treatment comprised 50.4 Gy/28 fractions 
external radiation with continual 5-fluorouracil. Four to six 
weeks after the radiochemotherapy, surgical resection was 
performed. Immunohistochemistry was applied to assess CD8+ 
expression in both the pretreatment biopsies and resected 
specimens.  
 
Results: During radiochemotherapy 30 patients (57%) had 
increased the density of CD8+ TILs, in 18 patients (34%) 
decreased, in 1 patient there was no change, in 4 patients it 
was not possible to assess the dynamics of the density of 
CD8+ TILs (in 2 patients due to insufficient amount of tissue 
for immunohistochemical analysis and in other 2 patients due 
to pathologic complete response after radiochemotherapy). 
The median of follow-up was 75 months (6.3 years). In 2 
patients resection with microscopic residual tumor (R1) was 
performed and for 51 patients radical resection with 
microscopically negative margins (R0) was performed. 
Downstaging after preoperative radiochemotherapy was 
observed in 34 patients (64%). Five-year overall survival was 
56% (95%CI: 43-70%). The density of CD8+ TILs was not 
significant in Cox regression analysis (p=0.16) or log-rank test 
(p=0.16). According to chi-square test (p=0.37) there was no 
significant impact of the increase of the density of CD8+ TILs 
after radiochemotherapy on downstaging. The increase of the 
density of CD8+ TILs after radiochemotherapy was associated 
with a trend of 2.5 longer overall survival in comparison with 
patients with the decrease of the density of CD8+ TILs after 
radiochemotherapy. 
 
Conclusion: In the present study we did not observe any 
predictive or prognostic significance of the density of CD8+ 
TILs in endoscopical biopsies before radiochemotherapy, in 
resection specimens after the radiochemotherapy nor in 
changes of the density of CD8+ TILs after radiochemotherapy. 
The limitation of our study is the number of patients (53). It 
is not excluded that in a larger number of patients predictive 
or prognostic significance of the density of CD8+ TILs could 
be detected. 
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Purpose or Objective: Tumor metastasis and tumor immune 
evasion present major challenges of cancer treatment. 
Radiotherapy has been demonstrated to overcome the 
immunosuppressive tumor microenvironment and anecdotal 
reports suggest that local tumor irradiation alone may also 
exert systemic or abscopal anti-tumor effects by immune-
response stimulation with subsequent control of non-
irradiated tumor metastases. This study aimed to assess 
abscopal effects of radiation alone and in combination with 
an mRNA-based tumor vaccination in a syngenic mouse 
model. 
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Material and Methods: Syngenic C57BL/6 mice were 
subcutaneously injected with ovalbumin-expressing murine 
thymoma cells (E.G7-OVA, 3×105) into the right hind leg of on 
day -13 and into the left flank on day -9. On days 0, 1 and 2, 
the primary tumors (right hind leg) were irradiated (IR) with 
fractions of 2 Gy photons by the use of a linear accelerator. 
The secondary tumors at the left flank were shielded and 
received only 1.1 ± 0.3% of the IR dose applied to the primary 
tumor as confirmed by film dosimetry. Twice per week, 
tumor length and width were measured by caliper for tumor 
volume calculation and vaccination groups were 
intradermally injected with the mRNA-based vaccine 
RNActive® encoding Ovalbumin beginning day 0. At the end 
of the experiments, the secondary tumors were analyzed for 
cytokine abundances by protein microarray. 
 
Results: Primary and secondary tumors of control mice 
developed with similar growth kinetics. IR and combined 
radioimmunotherapy significantly delayed tumor growth 
leading to primary tumor control in 15% and 53% of mice. 
Importantly, in secondary tumors with starting volumes below 
30mm³ radioimmunotherapy induced a significant growth 
delay compared to vaccination alone (p=0.002) and control 
group (p=0.01). IR alone delayed the growth of the 
secondary, unirradiated tumors in an unsignificant manner. 
Cytokine microarray analysis of the unirradiated secondary 
tumors showed significant differences in combined 
radioimmunotherapy for CCL5/RANTES and CXCL9/MIG 
expression as compared to the other groups, both suggesting 
increased T-cell activation. Similar but unsignificant trends 
could be observed for TNF-α, CCL3, IL-1α, VEGF, M-CSF and 
other cytokines. 
 
Conclusion:  
Immunotherapy can enhance radiation-induced abscopal 
effects in small immunogenic tumors. This effect exhibits the 
potential of a combined radioimmunotherapy for the control 
of micrometastases. The characterization of the underlying 
immunological processes has to await further experiments. 
 
Symposium: Modern ART based on functional / biological 
imaging  
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Developments in high-precision radiotherapy by means of on-
board imaging, such as IMRT and stereotactic radiotherapy, 
have extended the possibilities for dose escalation to tumor 
localizations, while de-escalating doses to surrounding 
normal tissues. Advances in imaging technologies allow for 
better differentiation of tumor extension and target 
localization. In addition to superior anatomical imaging 
possibilities, functional and molecular imaging can be utilized 
to convey information regarding inherent tumor 
characteristics relevant for prognostication and prediction of 
therapy response. In many different tumor types, studies 
have investigated the potential of especially magnetic 
resonance imaging (MRI) and positron emission tomography 
(PET) / computed tomography (CT) scan to bring various 
tumor features to light. Repetitive imaging of malignancies 
before and during treatment can give rise to response 
adaptive treatment as has been successfully shown by 
integrating 18F-Fluorodeoxyglucose (18F-FDG) PET/CT 
imaging in chemotherapy response evaluation of Hodgkin’s 
Lymphoma, in order to define the eventual radiotherapy 
target and dose or to avoid radiotherapy altogether. For 
response evaluation of Hodgkin’s Lymphoma on 18F-FDG 
PET/CT images, application of the internationally accepted 
Deauville criteria reduce interobserver variability and 
standardize response criteria. 
In many solid tumor types, numerous mostly single-center 
studies have described a plethora of functional or molecular 
imaging characteristics for description of tumor features, 
prognostication and prediction purposes, radiotherapy target 
delineation or direction of targeted therapy. This illustrates 
the drive towards personalized medicine in oncology, where 
individual therapy and therapy adaptation are based on 
specific patient and tumor characteristics. PET/CT studies 
concerning prognostic and predictive imaging properties have 
focused on depiction of tumor characteristics and their 
changes during therapy; such as metabolism (e.g. 18F-FDG 
PET), hypoxia (e.g. 18F-fluoromisonidazole PET, 18F-
fluoroazomycin arabinosine PET, Blood Oxygen Level-
dependent MRI), proliferation (e.g. 18F-fluorothymidine 
PET), cell membrane synthesis (e.g. 11C-choline PET), tumor 
cellularity (e.g. Diffusion-weighted MRI) or tumor perfusion 
(e.g. Dynamic Contrast-enhanced MRI). Clinical and pre-
clinical PET/CT studies have illustrated the possibility to 
quantify presence and abundance of targets for antibody-
based therapies, such as radiolabeled cetuximab in the case 
of the epidermal growth factor receptor. Studies on adaptive 
radiotherapy based on PET/CT imaging, in e.g. head-and-
neck squamous cell carcinoma and non-small cell lung 
cancer, have mainly focused on definition of radiotherapy-
resistant tumor subvolumes relevant for dose-escalation. 
Longer follow up results of these studies will reveal if these 
therapy intensifications will lead to better disease outcomes.  
What such imaging studies bring forward, is that different 
imaging modalities with different specific biological markers 
will define different tumor subvolumes, mostly with different 
spatial and temporal properties. The challenge is to define 
the correct individual therapy regulations for the correct 
tumor within the correct timeframe. Moreover, how can one 
reliably quantify the imaging signal, delineate radioresistant 
tumor subvolumes or evaluate therapy response, if most 
